HC Wainwright & Co. Reiterates Buy on Crescent Biopharma, Maintains $25 Price Target
Benzinga Newsdesk 1 year ago
NewsPrice TargetReiterationAnalyst Ratings
HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Crescent Biopharma (NASDAQ:CBIO) with a Buy and maintains $25 price target.
HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Crescent Biopharma (NASDAQ:CBIO) with a Buy and maintains $25 price target.